| Type 2 Diabetes Mellitus |
1 |
1 |
| Clinical Guidelines |
0 |
0.99 |
| DPP-4 Inhibitors |
0 |
0.52 |
| Chronic Kidney Disease |
0 |
0.42 |
| GLP-1 Receptor Agonist |
0 |
0.39 |
| Renal Failure |
0 |
0.38 |
| Hypoglycemia |
0 |
0.35 |
| Primary and Secondary Prevention of Coronary Artery Disease |
0 |
0.35 |
| Heart |
0 |
0.26 |
| Receptors |
0 |
0.26 |
| Heart Failure (HF) |
0 |
0.23 |
| Cardiovascular Risk Management |
0 |
0.22 |
| Cerebrovascular Accident |
0 |
0.22 |
| Renal Disease |
0 |
0.21 |
| Sulfonylureas |
0 |
0.17 |
| Weight Loss |
0 |
0.17 |
| Hemoglobin A1c |
0 |
0.12 |
| Obesity |
0 |
0.12 |
| Weight Management |
0 |
0.11 |
| Artificial Intelligence |
0 |
0.09 |
| Blood |
0 |
0.09 |
| Diet |
0 |
0.09 |
| Exercise |
0 |
0.09 |
| Hemoglobin |
0 |
0.09 |
| Infarction |
0 |
0.09 |
| Italy |
0 |
0.09 |
| Kidney |
0 |
0.09 |
| Shared Decision-Making |
0 |
0.09 |
| Healthcare and Medical Technology |
0 |
0.06 |
| Myocardial Infarction (MI) |
0 |
0.06 |